Literature DB >> 4208289

Pharmacokinetic studies of tobramycin and gentamicin.

V K Simon, E U Mösinger, V Malerczy.   

Abstract

Broth dilution susceptibility tests of 100 isolates of Pseudomonas aeruginosa and 101 isolates of Staphylococcus aureus against tobramycin (formerly nebramycin factor 6) and gentamicin showed that tobramycin was more effective against P. aeruginosa and less effective against S. aureus. The minimal inhibitory concentration of tobramycin against the Pseudomonas sp. isolates that required 5 mug of gentamicin per ml for inhibition ranged from 0.63 to 0.31 mug/ml. Peak concentrations in the blood of 10 healthy adults after intramuscular injection of 80 and 40 mg of tobramycin averaged 3.7 +/- 0.62 and 2.4 +/- 0.27 mug/ml, and declined to 0.56 +/- 0.05 and 0.26 +/- 0.02 mug/ml, respectively, after 6 h. The urine recovery averaged 60%. The half-life was 1.6 h. During continuous intravenous infusion of tobramycin and gentamicin (infusion rate 6.6 mg per h), blood levels at steady state were 0.94 +/- 0.10 and 1.04 +/- 0.06 mug/ml, respectively. For both antibiotics, the calculated distribution volume ranged from 15 to 17 liters. The renal clearance to tobramycin averaged 76% and that of gentamicin averaged 85% of the total clearance, indicating that the drugs are primarily eliminated by the kidneys. The present results suggest that tobramycin may be more successful in the treatment of Pseudomonas infections than gentamicin at the same dosage (80 mg intramuscularly three to four times daily).

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4208289      PMCID: PMC444432          DOI: 10.1128/AAC.3.4.445

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Gentamicin in urinary infections of children.

Authors:  R J Holt; R L Newman
Journal:  Arch Dis Child       Date:  1968-06       Impact factor: 3.791

2.  The dose, distribution, and excretion of gentamicin with speical reference to renal failure.

Authors:  J C Gingell; G D Chisholm; J S Calnan; P M Waterworth
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

3.  [Clinical experiences with gentamicin in the therapy of urinary tract infections].

Authors:  F W Reutter; H Modde
Journal:  Ther Umsch       Date:  1969-01

4.  Clinical use of gentamicin in ear, nose, and throat infections.

Authors:  P Federspil
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

5.  Nebramycin, a new broad-spectrum antibiotic complex. IV. In vitro and in vivo laboratory evaluation.

Authors:  W E Wick; J S Welles
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

6.  Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis.

Authors:  W M Stark; M M Hoehn; N G Knox
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

7.  Nebramycin, a new broad-spectrum antibiotic complex. II. Description of Streptomyces tenebrarius.

Authors:  C E Higgins; R E Kastner
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

8.  Nebramycin, a new broad-spectrum antibiotic complex. 3. Isolation and chemical-physical properties.

Authors:  R Q Thompson; E A Presti
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

9.  Dosage of gentamicin for pseudomonas infections.

Authors:  J H Darrell; P M Waterworth
Journal:  Br Med J       Date:  1967-05-27

10.  Gentamicin: clinical and laboratory studies in infants and children.

Authors:  A W Nunnery; H D Riley
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

View more
  26 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.

Authors:  G Jaffe; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

Review 3.  Antibacterial Drugs today: II.

Authors:  A P Ball; J A Gray; J M Murdoch
Journal:  Drugs       Date:  1975       Impact factor: 9.546

4.  Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin.

Authors:  R F Malacoff; F O Finkelstein; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

5.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 6.  Aminoglycosides: An Overview.

Authors:  Kevin M Krause; Alisa W Serio; Timothy R Kane; Lynn E Connolly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

Review 7.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

8.  The use of tombramycin in the management of severe infections. Clinical and pharmacological data.

Authors:  D Baron; H Drugeon; F Nicolas; A Courtieu
Journal:  Eur J Intensive Care Med       Date:  1976-09

9.  Therapy of Pseudomonas aeruginosa infections with tobramycin.

Authors:  D C Blair; F R Fekety; B Bruce; J Silva; G Archer
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

Review 10.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.